🔗 Permalink

Assignee profile:

Ascendis Pharma Endocrinology Division A/S

City:

Hellerup

Country:

Denmark

Published Applications:

Last publication date:

2025-09-25

Patent Grants:

Last grant date:

2025-05-20

Top Inventors for applications by Ascendis Pharma Endocrinology Division A/S

These are the the leading inventors for applications assigned to Ascendis Pharma Endocrinology Division A/S:

Grethe Norskov Rasmussen 9 Farum, Denmark
Thomas Wegge 8 Heidelberg, Germany
Harald Rau 8 Dossenheim, Germany
Susanne Kindermann 5 Liestal, Switzerland

Steen Jensen 4 Dragoer, Denmark
Thomas Kurpiers 3 Heidelberg, Germany
Torben Lessmann 3 Neustadt, Germany
Ulrich Hersel 3 Heidelberg, Germany

Evelyn Exner 3 Nussloch, Germany
Nina Schubert 3 Stuttgart, Germany
Kennett Sprogøe 3 Holte, Denmark
Joachim Zettler 2 Heidelberg, Germany

Torben Lessmann 2 Neustadt an der Weinstrasse, Germany
Alina Hermann 2 Schriesheim, Germany
Kennett SPROGØE 2 Hellerup, Denmark
Kennett Sprogøe 1 Hellerup, Denmark

Henrik Egesborg 1 Hellerup, Denmark
Steen Jensen 1 Dragoer, Germany
Anna Splanemann 1 Heldelberg, Germany
Susanne Kindermann 1 Heidelberg, Germany

Kennett Sprogøe 1 Palo Alto, CA United States
Joachim Zettler 1 Heidelerg, Germany
Thomas Wegge 1 Keidelberg, Germany
Anna Splanemann 1 Hedelberg, Germany

Torben Lebmann 1 Mannheim, Germany
Anna Splanemann 1 Heidelberg, Germany
Grethe Nørskov Rasmussen 1 Farum, Germany
Steen Jennsen 1 Dragoer, Denmark

Thomas Kurpiers 1 Heldelberg, Germany
Alina Hermann 1 Schrieshein, Germany
Harald Rau 1 Heidelberg, Germany

Recent patent applications by Ascendis Pharma Endocrinology Division A/S

Ascendis Pharma Endocrinology Division A/S based in Hellerup, DK has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-09-25

US20250295738A1

Human necessities

Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin

#2 | 2025-01-30

US20250032587A1

Human necessities

Novel Polymeric hGH Prodrugs

#3 | 2022-03-24 ✅ Patent 12,303,553 granted on 2025-05-20

US20220088147A1

Human necessities

Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

#4 | 2021-07-22 ✅ Patent 12,274,737 granted on 2025-04-15

US20210220442A1

Human necessities

PEGylated recombinant human growth hormone compounds

#5 | 2020-12-17 ✅ Patent 12,133,883 granted on 2024-11-05

US20200390864A1

Human necessities

Polymeric hGH prodrugs

#6 | 2020-08-20 ✅ Patent 12,226,457 granted on 2025-02-18

US20200261544A1

Human necessities

Dry growth hormone composition transiently linked to a polymer carrier

#7 | 2019-06-27 ✅ Patent 10,960,053 granted on 2021-03-30

US20190192634A1

Human necessities

PEGylated recombinant human growth hormone compounds

#8 | 2018-07-05 ✅ Patent 10,682,395 granted on 2020-06-16

US20180185452A1

Human necessities

Dry growth hormone composition transiently linked to a polymer carrier

#9 | 2017-12-14 ✅ Patent 10,799,563 granted on 2020-10-13

US20170354716A1

Human necessities

Polymeric hGH prodrugs

#10 | 2017-11-02 ✅ Patent 12,016,903 granted on 2024-06-25

US20170312342A1

Human necessities

Long-acting growth hormone treatment

#11 | 2017-03-02 ✅ Patent 9,919,033 granted on 2018-03-20

US20170056477A1

Human necessities

Dry growth hormone composition transiently linked to a polymer carrier

#12 | 2016-07-21 ✅ Patent 10,098,930 granted on 2018-10-16

US20160206702A1

Human necessities

PEGylated Recombinant Human Growth Hormone Compounds

Also check out Ascendis Pharma Endocrinology Division A/S's (Hellerup, Denmark) applicant profile with 11 patent applications submitted.

AssigneeID:

128397 ⎘